Title: The aromatase inhibitors in early breast cancer: who, when, and why?
Abstract: Medical Journal of AustraliaVolume 183, Issue 1 p. 24-27 Clinical Update The aromatase inhibitors in early breast cancer: who, when, and why? Ilona C Nordman MB BS, Ilona C Nordman MB BS Medical Oncology Registrar Sydney Cancer Centre, Royal Prince Alfred Hospital, Sydney, NSW.Search for more papers by this authorAndrew J Spillane BM BS, MD, FRACS, Andrew J Spillane BM BS, MD, FRACS Visiting Medical Officer in Surgery Sydney Cancer Centre, Royal Prince Alfred Hospital, Sydney, NSW.Search for more papers by this authorAnne L Hamilton MB BS, FRACP, Corresponding Author Anne L Hamilton MB BS, FRACP Medical Oncologist; and Senior Lecturer, University of Sydney [email protected] Sydney Cancer Centre, Royal Prince Alfred Hospital, Sydney, NSW.Correspondence: [email protected] for more papers by this author Ilona C Nordman MB BS, Ilona C Nordman MB BS Medical Oncology Registrar Sydney Cancer Centre, Royal Prince Alfred Hospital, Sydney, NSW.Search for more papers by this authorAndrew J Spillane BM BS, MD, FRACS, Andrew J Spillane BM BS, MD, FRACS Visiting Medical Officer in Surgery Sydney Cancer Centre, Royal Prince Alfred Hospital, Sydney, NSW.Search for more papers by this authorAnne L Hamilton MB BS, FRACP, Corresponding Author Anne L Hamilton MB BS, FRACP Medical Oncologist; and Senior Lecturer, University of Sydney [email protected] Sydney Cancer Centre, Royal Prince Alfred Hospital, Sydney, NSW.Correspondence: [email protected] for more papers by this author First published: 04 July 2005 https://doi.org/10.5694/j.1326-5377.2005.tb06882.xCitations: 8Read the full textAboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onFacebookTwitterLinkedInRedditWechat Abstract The aromatase inhibitors deplete oestrogen by inhibiting aromatase, the enzyme that synthesises oestrogen from androgens. They are effective as therapies for breast cancer only in postmenopausal women whose tumours express oestrogen or progesterone receptors. As adjuvant therapy, tamoxifen and the aromatase inhibitors have similar efficacy in the first 5 years of treatment. Aromatase inhibitors can be used as an alternative to tamoxifen in women with symptomatic intolerance or a contraindication to tamoxifen. Early data suggest that switching to an aromatase inhibitor after 2–5 years of tamoxifen therapy is beneficial in women with high-risk disease. Aromatase inhibitors are associated with more hot flushes than placebo, but with fewer hot flushes, less endometrial toxicity and venous thromboembolism, and more arthralgia, myalgia and bone fracture than tamoxifen. Citing Literature Volume183, Issue1July 2005Pages 24-27 RelatedInformation
Publication Year: 2005
Publication Date: 2005-07-01
Language: en
Type: review
Indexed In: ['crossref', 'pubmed']
Access and Citation
Cited By Count: 12
AI Researcher Chatbot
Get quick answers to your questions about the article from our AI researcher chatbot